Maine settles with Eli Lilly
Maine, along with 32 other states, today reached a record $62 million settlement with Eli Lilly and Company arising from the alleged improper marketing of the antipsychotic drug Zyprexa.
Maine Attorney General Steve Rowe alleged that Indianapolis, Ind.-based Eli Lilly engaged in unfair and deceptive practices when it marketed Zyprexa, which was first marketed in 1996 for use in adults with schizophrenia, for off-label uses and for failing to adequately disclose the drug's potential side effects to health care providers, according to a press release from the AG's office. Following a year and a half long investigation, Eli Lilly agreed to cease promoting Zyprexa for off-label uses that are not approved by the U.S. Food and Drug Administration.
Today's $62 million settlement is the largest consumer protection-based pharmaceutical settlement ever, following closely on the heels of the May 2008, $58 million agreement with Merck regarding its product Vioxx. Maine's share of the Eli Lilly settlement will be $1,020,609. Read the press release for more.
Most Recent
Most Recent
Comments